1. Home
  2. MEGL vs ERNA Comparison

MEGL vs ERNA Comparison

Compare MEGL & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Empire Global Limited

MEGL

Magic Empire Global Limited

HOLD

Current Price

$1.12

Market Cap

5.1M

Sector

Finance

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$11.80

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGL
ERNA
Founded
2016
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MEGL
ERNA
Price
$1.12
$11.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.9K
3.8M
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.13
52 Week High
$2.62
$15.88

Technical Indicators

Market Signals
Indicator
MEGL
ERNA
Relative Strength Index (RSI) 51.11 68.30
Support Level $1.01 $0.61
Resistance Level $1.39 $15.88
Average True Range (ATR) 0.09 2.70
MACD -0.00 0.31
Stochastic Oscillator 17.61 64.98

Price Performance

Historical Comparison
MEGL
ERNA

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: